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Abstract
Background
The epithelioid and sarcomatoid histologic variants of malignant pleural mesothelioma
(MPM) can be considered as E- and M-parts of the epithelial-mesenchymal transition (EMT)
axis; the biphasic being an intermediate. EMT is associated with an increase of stem cell
(SC) traits. We correlated the neural crest SC marker nestin and the EMT marker periostin
with histology, type of neo-adjuvant chemotherapy (CT) and overall survival (OS) of MPM
patients.
Patients and Methods
Tumor tissues of a historic cohort 1 (320 patients) and an intended induction chemotherapy
followed by extrapleural pneumonectomy (EPP) cohort 2 (145 patients) were immunohisto-
chemically H-scored (intensity of immunoreactivity multiplied by frequency of stained cells).
Paired chemo-naïve biopsies and -treated surgical specimens were available for 105/145
patients. CT included platinum/gemcitabine (Pla/Gem) or platinum/pemetrexed (Pla/Pem).
Results
Expression of any cytosolic nestin progressively increased from epithelioid to biphasic to
sarcomatoid MPM in cohort 1, whereas the diagnostic markers calretinin and podoplanin
decreased. In cohort 2, Pla/Pem CT increased the expression level of nestin in comparison
to Pla/Gem, whereas the opposite was found for periostin. In Pla/Pem treated patients, nes-
tin was higher in biphasic MPM compared to epithelioid. In addition to non-epithelioid histol-
ogy, any expression of nestin in chemo-naïve biopsies (median overall survival: 22 vs. 17
months) and chemo-treated surgical specimens (18 vs. 12 months) as well as high periostin
in biopsies (23 vs. 15 months) were associated with poor prognosis. In the multivariate sur-
vival analysis, any nestin expression in chemo-naïve biopsies proved to be an independent
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prognosticator against histology. In both pre- and post-CT situations, the combination of
nestin or periostin expression with non-epithelioid histology was particularly/ dismal (all p-
values <0.05).
Conclusions
The SC marker nestin and the EMT marker periostin allow for further prognostic stratifica-
tion among histologic variants of MPM. Their expression level is influenced by neo-adjuvant
chemotherapy.
Introduction
Malignant pleural mesothelioma (MPM) is a highly aggressive, asbestos-related neoplasm
characterized by rapid and diffuse local growth, late metastases, and early death. MPM elabo-
rates the two distinct histologic variants epithelioid and sarcomatoid. The mixture of both is
called biphasic.
Mesothelial cells are derived from the coelomic cavity lining cells which originate from
mesodermal mesenchyme via mesenchymal-epithelial transition (MET), leading to co-expres-
sion of the intermediate filaments cytokeratin and vimentin. The opposite epithelial-mesen-
chymal transition (EMT) from epithelioid to sarcomatoid mesothelioma in turn reflects a
reversion of embryological development and is associated with increased tumor aggressiveness
and poor survival, respectively. During this transdifferentiation, all relevant diagnostic meso-
thelioma markers such as calretinin, podoplanin detected by the D2-40 antibody, WT1 and
CK5/6 decrease. Previously, we found a calretinin expression in 91% of epithelioid and 57% of
sarcomatoid tumors, respectively. D2-40 immunoreactivity was present in 66% of epithelioid
and 30% of sarcomatoid [1]. Few data are available on markers that increase towards sarcoma-
toid differentiation or allow for further stratification of prognosis among histologic variants.
EMT has been shown to confer stem cell (SC) traits to tumor cells [2] and one therefore
expects a higher expression of EMT/SC markers in sarcomatoid tumors. We investigated the
well-recognized EMT marker N-glycoprotein periostin, both tumor-cell associated and stromal
[3–4] and found it to be associated with sarcomatoid MPM [5]. Periostin, tenascin and osteo-
pontin are the main non-structural secreted matricellular proteins which form a key compo-
nent of both desmoplastic tumor stroma and granulation tissue [6]. In asbestos-exposed
persons, serum osteopontin levels were shown to be different in cancer-free versus MPM
patients [7].
The intermediate filament protein nestin is a neuroectodermal stem/progenitor cell marker
[8–9]. Self-renewing melanoma progenitor cells expressed nestin [10] and both intermediate
filament proteins nestin and vimentin were found to colocalize in melanoma [11]. Next to neu-
ral cells and melanocytes, the neural crest also generates mesenchymal cell types and nestin
was detected in mesodermal cells like fibroblasts or hepatic stellate cells [12–13]. In the kidney,
nestin-positive tubular cells co-expressed vimentin, suggesting these cells reverted to a mesen-
chymal phenotype [14] and Nes-Cre1-mediated recombination occurred in progenitor cell
types of the developing mesonephros [8]. Finally, nestin positive mesenchymal stem cells
(MSCs) were found to constitute an essential hematopoietic stem cell (HSC) niche component
in the bone marrow [15].
Recent work on nestin, mesothelin and epithelial membrane antigen (EMA) expression in
developing and adult serous membranes indicated that superficial pleural mesothelial cells are
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always nestin negative, whereas in the submesothelial layer cells nestin expression decreases
during development. Nestin protein expression was immunohistochemically detected in 13%
of the tumor cells of 6 epithelioid mesotheliomas [16].
Herein, we addressed the hypothesis that expression of the SC marker nestin or the EMT
marker periostin may stratify with the histologic variant and the overall survival (OS) of MPM
patients. Further, we investigated the effect of neo-adjuvant chemotherapy (CT) using plati-
num/gemcitabine (Pla/Gem) or platinum/pemetrexed (Pla/Pem) on the expression of these
markers. A historic test cohort 1 of 320 patients and a cohort 2 consisting of 145 patients with
intention-to-treat (ITT) by induction chemotherapy followed by extrapleural pneumonectomy
were investigated by IHC on tissue microarrays. The ITT patient cohort 2 included paired
chemo-naïve diagnostic biopsies and chemo-treated surgical specimens.
Materials and Methods
Patient cohorts and MPM histology
Two MPM patient cohorts were set up. Cohort 1 ranged from 1975 to 2004 and comprised 320
patients from whom mesothelioma and lung tissue was sent to the Zurich Pneumoconiosis
Research Group for mineralogical assessment of dust exposure by TEM-EDX (transmission
electron microscopy, energy dispersive X-ray spectroscopy). This cohort consisted mostly of
autopsy cases with only limited clinical data. Cohort 2 spans the decade of 1999 to 2009 and
includes 145 non-redundant MPM patients referred to the University Hospital Zurich for
intended multimodality treatment with induction chemotherapy followed by extrapleural
pneumonectomy (EPP). Paraffin blocks of pre-chemotherapy (CT) diagnostic pleural biopsies
were gathered from all Institutes of Pathology of referral hospitals. All cases were entirely
reviewed for histologic classification on both whole sections used for the sign-out and TMA
cores. MPM was considered biphasic if the minor moiety exceeded 10% according to the WHO
guidelines. Written informed consent was given by the patients and documented on the clinical
information system at the time of surgery. The study was approved by the Ethical Commission
of the Canton of Zurich under reference number KEK ZH-Nr. 29-2009/14.
Tissue microarray construction and immunohistochemistry
MPM TMAs were constructed as previously described (1). Four (surgical specimens) or two
(diagnostic biopsies) tissue cores of 0.6 mm diameter were taken from 1 or 2 most representa-
tive tumor blocks and transferred into the recipient paraffin block. Concerning the biphasic
variant, cores were punched out of an area considered to be biphasic on the corresponding HE
(hematoxylin-eosin) whole section. In total, 7 TMAs were manufactured. TMA sections were
stained on an automated IHC platform (Ventana Medical System, Tucson, AZ, USA) with the
Mab anti-nestin (clone 10C2, 1:100 dilution, Chemicon International Inc., Temecula, CA,
USA). Detection was performed with respective secondary antibody and Ultraview Amp kit
(Ventana). Staining of periostin, calretinin and podoplanin (D2-40 antibody) was performed
as previously described [1,5].
Cell blocks
The biphasic MPM cell line SPC212 and the immortalized mesothelial cell line MET5A were
grown in RPMI 1640, supplemented with 10% fetal bovine serum. Cells were centrifuged at
2000 x g for 10 min at room temperature, clotted by addition of plasma (4 droplets) and throm-
bin (1 droplet) and processed as formalin-fixed paraffin-embedded (FFPE) cell blocks as
described [17].
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Data interpretation and statistical analysis
The intensity of tumor-associated cytosolic immunoreactivity was scored semi-quantitatively 0
(negative), 1 (weak), 2 (moderate) or 3 (strong). The frequency of stained tumor cells was
scored 0, 10 (1–10%), 50 (11–50%) or 100 (51–100%). The product of intensity of immunore-
activity and frequency of stained cells was called H-score (I x F, range 0–300). In order to get
an H-score per patient the 4 cores or the 2 cores were summed up and divided by 4 or 2, respec-
tively. Non-parametric tests were used to evaluate the association of H-scores and histology
(Mann-Whitney U test). To compare the change of expression in paired chemo-naïve and
-treated samples the Wilcoxon signed rank test was used. Tumor response to chemotherapy
was evaluated based on modified Response Evaluation Criteria in Solid Tumors (RECIST)
[18]. The association of modified RECIST criteria and H-scores was tested with the Kruskal-
Wallis test for independent samples. For survival analyses the H-score was dichotomized clos-
est to the median. To analyse the effect of marker expression and histology on survival, 4
groups were made with low/high marker expression and epithelioid/non-epithelioid histology.
The Kaplan-Meier method was applied using log rank tests. Patients having a survival 1
month post-surgery were excluded. Overall survival (OS) represents survival from the date of
diagnosis to the time-point of death for diagnostic biopsies and from the date of surgery to the
time point of death for surgical specimens. If no event occurred the OS was calculated until last
follow-up and the cases were censored in the analysis. For multivariate analysis significant
parameters were introduced into a Cox regression model, using histology as categorical vari-
able. P-values<0.05 were considered significant. All statistical analyses were performed on
SPSS version 22 software (SPSS Inc., Chicago, USA).
Results
Cohort description
Table 1 summarizes the clinico-pathologic data of the 2 cohorts: In total, tumor tissue of 465
MPM patients was analysed. The median overall survival (OS) of cohort 2 was 18 months
(95% confidence interval (CI): 13–23 months) and 98% of the patients deceased during the
observation time. All cohort 2 patients were intended to be treated with induction chemother-
apy followed by EPP and therefore received 3 cycles of Pla/Gem (n = 59) or Pla/Pem (n = 85).
One patient received another regimen. EPP was thereafter performed in 107 (74%) of patients,
the others underwent pleurectomy or thoracotomy or had no surgery.
Nestin and periostin expression in MPM cohort 1 and 2
Robust nestin immunoreactivity was observed in the biphasic mesothelioma cell line SPC212
and the MPM tumor tissues (Fig 1) as well as in the immortalized mesothelial cell line MET5A
(data not shown). Both the intermediate filament protein nestin and the tumor cell-associated
N-glycoprotein periostin were expressed in the cytosol. The nestin and periostin H-score
ranges are shown in Table 1. Thus, any nestin expression was found in 38 to 41% of MPM in
both cohorts. In the pre-chemotherapy biopsies of cohort 2, 8% of tumors were completely
negative for periostin. The majority displayed a weak cytosolic expression with H-score up
to 100.
Correlation of nestin and diagnostic epithelioid markers with histology in
cohort 1
In cohort 1, nestin immunoreactivity increased progressively from epithelioid (median: 0 inter-
quartile range (IQR): 0–0) to biphasic (median: 0, IQR: 0–100) to sarcomatoid MPM (median
Nestin in Pleural Mesothelioma
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50, IQR: 0–200), whereby all transitions including epithelioid-sarcomatoid, epithelioid-
biphasic and biphasic-sarcomatoid were significant. The opposite was observed for the diag-
nostic epithelioid markers calretinin and podoplanin, recognized by the D2-40 antibody
(Fig 2).
Correlation of nestin and periostin with neo-adjuvant chemotherapy and
histology in cohort 2
In cohort 2, the protein expression levels of periostin but not nestin significantly increased
after neo-adjuvant chemotherapy (Table 2). When comparing the two neo-adjuvant regimens,
we observed that the expression of periostin was significantly higher after Pla/Gem compared
to Pla/Pem. The opposite was found for nestin: Its immunoreactivity was significantly lower
after Pla/Gem compared to Pla/Pem.
Table 1. Summary of clinico-pathological and immunohistochemical data.
Cohort 1 Cohort 2
N patients 320 145
Time period 1975–2004 1999–2009
Intervention EPP 107 (74%)
Pleurectomy 8 (5%)
Thoracotomy 16 (11%)
No surgery 14 (10%)
Any Surgery 57 (18%)
Autopsy 263 (82%)
RECIST* Partial response (PR) 29 (30%)
Stable disease (SD) 42 (43%)
Progressive disease (PD) 26 (27%)
Median age (range) 64 (32–95) 61 (36–72)
Sex male 303 (95%) 133 (92%)
female 17 (5%) 12 (8%)
pre CT post CT
118 patients 133 patients
Histology epithelioid 129 (40%) 75 (64%) 73 (55%)
biphasic 144 (45%) 38 (32%) 52 (39%)
sarcomatoid 47 (15%) 5 (4%) 8 (6%)
Nestin H-score 0 197 (62%) 66 (65%) 72 (59%)
1–100 82 (26%) 27 (26%) 42 (34%)
101–200 24 (7%) 6 (6%) 5 (4%)
201–300 17 (5%) 3 (3%) 3 (3%)
Periostin H-score 0 9 (8%)
1–100 84 (71%) 82 (62%)
101–200 19 (16%) 31 (24%)
201–300 6 (5%) 19 (14%)
In cohort 2, the distribution of immunohistochemical H-scores (intensity of immunoreactivity multiplied by frequency of stained cells) is indicated for both
pre-and post-chemotherapy (pre-CT/post-CT) biopsies and surgical specimens, respectively. amodiﬁed RECIST criteria were only available for 97
patients.
doi:10.1371/journal.pone.0139312.t001
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Fig 1. IHC examples for nestin and periostin.Upper left: Sarcomatoid MPM and the biphasic mesothelioma cell line SPC212 (insert). Upper right: Biphasic
MPM tissue core with >10% epithelioid moiety (triangle) and predominant sarcomatoid differentiation (asterisk). Arrow = nestin-positive vessel endothelia.
Lower left: Arrow = tumor cell-associated cytosolic periostin, triangle = stromal periostin. Lower right: Arrow = tumor cell-associated periostin,
triangle = stromal periostin along vessel structures. Original magnifications 100x (upper right), 200x (other 3 panels) and400x (insert).
doi:10.1371/journal.pone.0139312.g001
Fig 2. Association of markers with histology in cohort 1.H-scores of nestin (A) were significantly higher in sarcomatoid MPMwhereas the diagnostic
epithelioid markers podoplanin/D2-40 (B) and calretinin (C) were significantly decreased in sarcomatoid MPM; Mann-Whitney U tests.
doi:10.1371/journal.pone.0139312.g002
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Itemization of neo-adjuvant chemotherapy according to histology (Fig 3) yielded following
results: A significant increased nestin protein expression was observed in Pla/Pem treated
biphasic MPM in comparison to epithelioid (Fig 3C). Periostin protein expression was higher
in chemo-naïve sarcomatoid MPM compared to epithelioid (Fig 3D). No significant different
expression among histologic variants was observed after Pla/Gem or Pla/Pem chemotherapy.
Table 2. Change of nestin and periostin expression after neo-adjuvant chemotherapy.
Nestin H-score Periostin H-score
median (IQR) p median (IQR) p
Neo-adj. CT Chemo - Chemo + Chemo - Chemo +
0 (0–10) 0 (0–10) n.s. 20 (10–100) 75 (15–150) 0.002
CT regimen Pla/Gem Pla/Pem Pla/Gem Pla/Pem
0 (0–0) 3 (0–10) 0.024 110 (20–188) 33 (13–150) 0.027
Neo-adj. CT: Comparison of nestin and periostin H-scores in chemo-naïve biopsies (Chemo-) with surgical specimens after neo-adjuvant chemotherapy
(Chemo +) (paired samples Wilcoxon signed rank test). CT regimen: Comparison of marker expression after application of two different chemotherapy
regimens: Pla/Gem, platinum + gemcitabine versus Pla/Pem, platinum + pemetrexed (Mann-Whitney U test for independent samples). IQR: interquartile
range; CT: chemotherapy.
doi:10.1371/journal.pone.0139312.t002
Fig 3. Associations of markers with histology according to neo-adjuvant CT. Box plots of nestin (A-C) and periostin (D-F) expression correlated with
histologic variant in cohort 2 in chemo-naïve biopsies (A/D) and surgical specimens treated with with Pla/Gem (B/E) or Pla/Pem (C/F); Mann-Whitney U tests.
doi:10.1371/journal.pone.0139312.g003
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No significant association between responses to induction chemotherapy (partial response
vs. stable disease vs. progressive disease) and the nestin as well as periostin H-scores
before and after chemotherapy could be detected. There was also no significant association
between response and H-score when the Pla/Gem and Pla/Pem treated patients were ana-
lysed separately.
Association with overall survival
As shown in Table 3, epithelioid histology was associated with longer OS compared to non-epi-
thelioid in chemo-naïve and chemo-treated samples. High expression of periostin in chemo-
naïve samples was associated with shorter OS. Expression of nestin in chemo-naïve as well as
chemo-treated samples was also associated with decreased OS. Combination of histology with
Table 3. Univariate analysis of overall survival.
n Median OS 95% CI p
Chemo-naïve samples
Histology epithelioid 74 23 20–26 0.016
non-epithelioid 39 14 10–18
Nestin no expression 64 22 17–27 0.017
expression 33 17 9–24
Periostin low H-score ( 20) 62 23 20–26 0.043
high H-score (> 20) 51 15 9–21
Histology + nestin no nestin expression + epithelioid 47 24 17–31 0.002
no nestin expression + non-epithelioid 17 15 11–19
nestin expression + epithelioid 20 19 11–28
nestin expression + non-epithelioid 13 10 7–13
Histology + periostin low periostin H-score + epithelioid 46 22 19–25 0.001
low periostin H-score + non-epithelioid 16 25 22–28
high periostin H-score + epithelioid 28 23 18–29
high periostin H-score + non-epithelioid 23 11 6–16
Chemo-treated samples
Histology epithelioid 70 19 15–24 0.003
non-epithelioid 55 11 9–14
Nestin no expression 67 18 14–22 0.038
expression 47 12 2–21
Periostin low H-score ( 75) 63 19 17–21 n.s.
high H-score (> 75) 61 16 10–22
Histology + nestin no nestin expression + epithelioid 43 22 13–30 0.008
no nestin expression + non-epithelioid 24 11 8–15
nestin expression + epithelioid 21 18 13–23
nestin expression + non-epithelioid 26 7 3–12
Histology + periostin low periostin H-score + epithelioid 38 19 14–24 0.005
low periostin H-score + non-epithelioid 25 14 5–23
high periostin H-score + epithelioid 31 18 12–25
high periostin H-score + non-epithelioid 30 10 6–14
Association of histologic variant as well as nestin and periostin H-scores (alone or in combination) in chemo-naïve biopsies and chemo-treated surgical
specimens with patient’s overall survival (OS) indicated. Median OS was calculated in months from the date of diagnosis for chemo-naïve and from the
date of surgery for chemo-treated samples. P-value was determined by log rank test. CI: conﬁdence interval.
doi:10.1371/journal.pone.0139312.t003
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marker expression gave following results: Patients with an epithelioid MPM that showed no
expression of nestin in the untreated sampled showed the longest median OS (24 months)
whereas patients with non-epithelioid MPM and expression of nestin had the shortest OS (10
months) of the 4 groups. Patients with a non-epithelioid MPM and high periostin levels in
chemo-naïve samples had a significantly worse median OS (11 months) than the other 3
groups (median OS 22–25 months). In chemo-treated surgical specimens, patients with non-
epithelioid MPM and expression of nestin or high expression of periostin had a shortened
median OS.
The Kaplan-Meier curves for nestin expression in chemo-naïve biopsies and the combina-
tion of nestin and histology in chemo-treated surgical specimens are presented in Fig 4.
Finally, the multivariate analysis of categorized histology together with marker expression
(Table 4) revealed that histology and nestin expression are independent prognosticators of
Fig 4. Kaplan-Meier curves. Survival curves presented for nestin expression in chemo-naïve biopsies (A) and the combination of nestin and histology in
chemo-treated surgical specimens (B).
doi:10.1371/journal.pone.0139312.g004
Table 4. Multivariate analysis of overall survival.
HR (95% CI) p
Chemo-naïve biopsies (n = 97)
Histotype <0.001
Biphasic vs. epithelioid 1.8 (1.1–2.8) 0.023
Sarcomatoid vs. epithelioid 13.9 (4.5–43.1) <0.001
Nestin (expression vs. no expression) 1.6 (1.0–2.5) 0.035
Periostin (high (>20) vs. low (20) H-score) 1.2 (0.8–1.9) n.s.
Chemo-treated surgical specimens (n = 114)
Histotype 0.012
Biphasic vs. epithelioid 1.7 (1.1–2.5) 0.014
Sarcomatoid vs. epithelioid 2.3 (1.1–5.1) 0.036
Nestin (expression vs. no expression) 1.5 (1.0–2.2) n.s.
Periostin (high (>75) vs. low (75) H-score) 1.4 (0.9–2.0) n.s.
Categorized histology and dichotomized H-scores of nestin and periostin were included in the multivariate
Cox regression analysis for both chemo-naïve biopsies and chemo-treated surgical specimens. HR: hazard
ratio; CI: conﬁdence interval.
doi:10.1371/journal.pone.0139312.t004
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survival in chemo-naïve biopsies whereas only histology remains an independent prognosti-
cator in chemo-treated surgical specimens
Discussion
In this study, we show that any expression of the neural crest stem cell factor nestin as well as
high expression of the EMT protein periostin are associated with decreased overall survival of
MPM patients when assessed by immunohistochemistry in chemo-naïve biopsies. In this set-
ting, nestin proves to be an independent prognosticator against categorized histology. Further,
any nestin expression in chemo-treated surgical specimens is also associated with decreased
survival, a combination with non-epithelioid histology being particularly dismal. Neo-adjuvant
chemotherapy using Pla/Pem increases the expression level of nestin in comparison to Pla/
Gem, whereas the opposite is found for periostin. Nestin expression is significantly higher in
biphasic and sarcomatoid MPM of the historic cohort 1 and in Pla/Pem treated biphasic MPM
of the ITT cohort 2 in comparison to epithelioid tumors.
Expression of the neural crest stem cell marker nestin in MPM
Herein, we found that most mesotheliomas (59–65%) were negative for nestin. In up to 5% we
observed a strong staining (H-score of>201). According to the literature, a high nestin expres-
sion was observed in 25% (14/56) of primary melanomas, 50% (84/165) of melanoma metasta-
ses and 40% (21/53) of melanoma cell lines [19]. In serous ovarian carcinoma, nestin was
detected in 33% of the tissues and its overexpression correlated with cisplatin-based CT resis-
tance and shorter OS [20]. In MPM, any nestin expression was observed in 13% of the tumor
cells of 6 epithelioid MPM [16].
Nestin is a class IV intermediate filament (IF) protein that copolymerizes into heteromeric
filaments with class III IF proteins, mostly vimentin [11], thereby connecting the components
of the cytoskeleton, coordinating changes in cell dynamics and contributing to vimentin disas-
sembly during mitosis. Anchoring of the glucocorticoid receptor (GR) to colocalized cytosolic
nestin-vimentin heterodimers was found to be related to high proliferation rate and poor prog-
nosis [11, 21]. It may be interesting to study this mechanism in deciduoid mesothelioma which
is particularly rich in vimentin filaments, as we have described previously [22]. Conceivably,
the relative protein expression of both vimentin and nestin intermediate filaments may be
related to biphasic/sarcomatoid differentiation and aggressiveness, respectively.
Expression of stem cell and EMT markers in the histologic variants of
MPM
We have previously investigated the EMT marker protein periostin on the MPM cohort 1 and
have found it to be associated with the sarcomatoid variant [5]. This prompted us to test if a
similar increase of the stem cell factor nestin exists along the EMT axis. In the historic cohort
1, an increase of nestin towards biphasic and sarcomatoid differentiation was found. In the ITT
cohort 2, such an increase was significant only for Pla/Pem treated biphasic MPM compared to
epithelioid. Statistics of the second cohort was restricted due to the low number of sarcomatoid
MPM (n = 4 each for Pla/Gem and Pla/Pem neo-adjuvant CT, respectively). In conclusion, a
transition of epithelioid to biphasic MPMmay be associated with an increase of stem cell traits
when applying certain types of CT. In a previous study we identified side population (SP) drug
effluxing cells with self-renewal properties and increased chemoresistance among MPM cell
lines and tumor-derived primary cell cultures [23]. Compared to the non-SP (NSP) fraction,
the SP fraction led to development of mesotheliomas characterized by mesenchymal morphol-
ogy and increased tumorigenicity. Other authors reported that non-epithelioid MPMs had
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lower E-cadherin but higher Snail, Twist and Zeb1 expression as well as a higher proliferation
rate [24–25]. Transcriptome analysis identified two MPM subgroups C1/C2, whereby C2
included all sarcomatoid and desmoplastic cases with mesenchymal phenotype [26].
EMT/SCmechanism in malignant pleural mesothelioma
EMT was proposed to be a mechanism for generation of cancer stem cells (CSCs) endowed
with a more invasive and metastatic phenotype [2]. E.g. EMT of immortalized human mam-
mary epithelia resulted in acquisition of mesenchymal and stem cell properties [27]. Such
EMT-derived cells exhibited a multi-lineage differentiation potential similar to mesenchymal
stem cells (MSC). Therefore, it was hypothesized that EMT programs emerge as important reg-
ulators of phenotypic plasticity in cancer cells, including their entrance into stem-cell states
[28]. Yet, the frequency of CSCs in a given tumor and the definition of their stem-cell state,
respectively, are highly debated. It is unclear if SC markers are restricted to bona fide CSCs that
may be defined in a strict manner as being able to create an exact tumor phenocopy when
transplanted from one mouse to the next, or if SC marker expression as assessed by IHC or
RT-PCR extends into the cancer progenitor cell pool or even into the pool of differentiated
cancer cells, reflecting rather histology plasticity with elaboration of stem cell traits.
The EMT concept has been investigated so far mostly for malignant epithelial tumors, thus
by definition carcinomas and corresponding cell lines derived from them. In some organs like
e.g. lung or bladder, sarcomatoid carcinomas may develop and are well recognized by their
spindle cell phenotype. These tumors co-express cytokeratin and vimentin but generally they
are rare and display a heterogeneous histology, mixed with adeno- or squamous cell carcinoma
parts, making the analysis of the EMT impact on e.g. overall survival difficult. Clinically more
frequent are biphasic tumors such as MPM, which are characterized by a constitutive intrinsic
switch between an epithelial, called epithelioid, and a mesenchymal, called sarcomatoid, differ-
entiation. Mesothelial cells are successors of the coelomic epithelium which originates from
mesodermal mesenchyme via MET. The EMT transition from epithelioid to sarcomatoid
MPM histology in turn reflects a reversion of embryological development. Thus, one may pos-
tulate that sarcomatoid MPM is more undifferentiated, similar to the embryonic mesodermal
original tissue. In general, we believe that MPM is one of the best human in-vivo models to
study the EMT/MET pathways.
Effect of neo-adjuvant chemotherapy on marker expression
MPM displays a high intrinsic chemotherapy resistance with poor response rates<20%. Pla/
Gem containing neo-adjuvant CT was administered in 59 patients, Pla/Pem in 85 patients,
allowing for further statistical analysis. As platinum was included in both regimens, it is con-
ceivable to attribute differences in immunoreactivity to Gem vs. Pem. The stem cell marker
nestin and the EMT marker periostin showed a different alteration of immunoreactivity in
response to these 2 regimens: Nestin expression increased, but periostin decreased in Pla/Pem
compared to Pla/Gem chemotherapy.
The antimetabolite gemcitabine (Gemzar1) is a pyrimidine nucleoside analog which
replaces cytidine during DNA replication and blocks the active site of ribonucleotide reductase
(RNR). Gemcitabine-treated MPM tissues displayed higher periostin in comparison to the
median of any chemotherapy (H-score 110 versus 75). This corroborates data on pancreatic
carcinomas: Gem-resistant tumor cells were reported to display EMT features including spin-
dle-shaped morphology, increased migration and reduced adhesion. Increase of vimentin as
well as the SC markers CD24 and 44 was associated with decreased E-cadherin [29].
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Pemetrexed (Alimta1) is a folate antimetabolite inhibiting thymidylate synthase, dihydro-
folate reductase and glycinamide ribonucleotide formyltransferase, 3 enzymes of the purine
and pyrimidine synthesis pathway. This drug is especially used for MPM CT. We have previ-
ously shown that neo-adjuvant CT, both Pla/Gem and Pla/Pem, induce senescence markers
like p21 or plasminogen activator inhibitor-1 (PAI-1) in MPM [30]. A similar study reported
the induction of SASP (senescence-associated secretory phenotype) by pemetrexed [31].
Thereby, conditioned media from senescent MPM triggered the emergence of EMT as well as
clonogenic and chemoresistant cell subpopulations with high levels of ALDH (aldehyde dehy-
drogenase) activity. In here, we observed a higher expression of nestin after neo-adjuvant
pemetrexed in comparison to gemcitabine, indicating that the former drug may be more effec-
tive in activating its expression.
This opens up the most intriguing question to what degree such induction chemotherapy
creates a subsequent intrinsic chemotherapy resistance itself via induction of EMT/SC traits.
At least for gemcitabine, one may hypothesize that this drug favours a fibrotic remodelling of
the peritumoral stroma containing increased amounts of the non-structural matricellular N-
glycoprotein periostin.
There was no significant association with response to induction chemotherapy using the
computer tomography based RECIST criteria. The major RECIST parameter is the total tumor
thickness measured perpendicular to the chest wall and the mediastinum, respectively. When
evaluating surgical EPP specimens on whole sections from several tumor blocks, chemoresis-
tance is often observed in MPM. Typically, vital areas of 50 to>90% of total tumor cells are
intermingled with minor areas of focal response presenting as necrosis or foamy cell degenera-
tion. As MPM is a multifocal disease, correlation of marker expression with response would
most likely need precise topographic mapping between hot/cold spots on positron-emission
tomography/computer tomography (PET/CT) and histologic sectioning at the very same posi-
tion. Non-tumoral inflammatory fibrosis and giant-cell reaction to talc pleurodesis will
although also contribute to glucose uptake.
In summary, our study shows that the stem cell factor nestin is a prognosticator for overall
survival of MPM patients and may allow for further stratification together with the histologic
variant.
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